6533b82efe1ef96bd12925b2

RESEARCH PRODUCT

P-26 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma

Ken KatoH. CastroTobias ArkenauJ. WangCrystal S. DenlingerY.-j. BangJ. TaberneroMarkus MoehlerJ. LiR. Xu

subject

Chemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologyGastroesophageal Junction AdenocarcinomaPlaceboGastroenterologyFirst line therapyOncologyInternal medicinemedicineIn patientbusinesshttps://doi.org/10.1016/j.annonc.2020.04.108